Loading...
•
Jun 30, 2023
Vaxart Q2 2023 Earnings Report
Announced second quarter 2023 financial results and provided business update.
Key Takeaways
Vaxart reported a revenue of $1.4 million and a net loss of $22.6 million for the second quarter of 2023. The company's cash runway has been extended into Q3 2024.
Reported positive preliminary topline data from Phase 2 bivalent norovirus vaccine candidate.
Advanced oral pill vaccine programs and delivered on planned timelines.
Anticipate reporting topline data from GI.1 norovirus challenge study during the third quarter.
Ended the second quarter with $67.9 million in cash, cash equivalents, restricted cash and marketable securities.
Vaxart
Vaxart
Forward Guidance
Vaxart continues to make progress on its anticipated milestones in 2023.
Positive Outlook
- Topline data from the ongoing Phase 2 challenge study of Vaxart’s GI.1 norovirus vaccine candidate is expected in Q3 2023.
- Initiation of a Bill & Melinda Gates Foundation-funded clinical trial to evaluate the ability of Vaxart’s norovirus vaccine candidate to induce antibodies in breast milk and transfer of antibodies to young infants.